S&P 500   4,531.48 (-0.10%)
DOW   35,483.07 (-0.35%)
QQQ   376.48 (+0.40%)
AAPL   149.42 (+0.11%)
MSFT   309.34 (+0.63%)
FB   342.07 (+0.38%)
GOOGL   2,832.41 (-0.10%)
TSLA   896.92 (+3.59%)
AMZN   3,439.26 (+0.71%)
NVDA   225.14 (+1.86%)
BABA   178.13 (+0.54%)
NIO   40.44 (+1.66%)
CGC   14.40 (+2.06%)
GE   104.29 (-1.61%)
AMD   118.46 (+1.78%)
MU   68.02 (-0.37%)
T   25.86 (-0.19%)
F   16.33 (+1.81%)
ACB   7.63 (-0.39%)
DIS   170.76 (+0.12%)
PFE   42.56 (-0.56%)
BA   215.37 (-0.37%)
AMC   41.24 (+0.88%)
S&P 500   4,531.48 (-0.10%)
DOW   35,483.07 (-0.35%)
QQQ   376.48 (+0.40%)
AAPL   149.42 (+0.11%)
MSFT   309.34 (+0.63%)
FB   342.07 (+0.38%)
GOOGL   2,832.41 (-0.10%)
TSLA   896.92 (+3.59%)
AMZN   3,439.26 (+0.71%)
NVDA   225.14 (+1.86%)
BABA   178.13 (+0.54%)
NIO   40.44 (+1.66%)
CGC   14.40 (+2.06%)
GE   104.29 (-1.61%)
AMD   118.46 (+1.78%)
MU   68.02 (-0.37%)
T   25.86 (-0.19%)
F   16.33 (+1.81%)
ACB   7.63 (-0.39%)
DIS   170.76 (+0.12%)
PFE   42.56 (-0.56%)
BA   215.37 (-0.37%)
AMC   41.24 (+0.88%)
S&P 500   4,531.48 (-0.10%)
DOW   35,483.07 (-0.35%)
QQQ   376.48 (+0.40%)
AAPL   149.42 (+0.11%)
MSFT   309.34 (+0.63%)
FB   342.07 (+0.38%)
GOOGL   2,832.41 (-0.10%)
TSLA   896.92 (+3.59%)
AMZN   3,439.26 (+0.71%)
NVDA   225.14 (+1.86%)
BABA   178.13 (+0.54%)
NIO   40.44 (+1.66%)
CGC   14.40 (+2.06%)
GE   104.29 (-1.61%)
AMD   118.46 (+1.78%)
MU   68.02 (-0.37%)
T   25.86 (-0.19%)
F   16.33 (+1.81%)
ACB   7.63 (-0.39%)
DIS   170.76 (+0.12%)
PFE   42.56 (-0.56%)
BA   215.37 (-0.37%)
AMC   41.24 (+0.88%)
S&P 500   4,531.48 (-0.10%)
DOW   35,483.07 (-0.35%)
QQQ   376.48 (+0.40%)
AAPL   149.42 (+0.11%)
MSFT   309.34 (+0.63%)
FB   342.07 (+0.38%)
GOOGL   2,832.41 (-0.10%)
TSLA   896.92 (+3.59%)
AMZN   3,439.26 (+0.71%)
NVDA   225.14 (+1.86%)
BABA   178.13 (+0.54%)
NIO   40.44 (+1.66%)
CGC   14.40 (+2.06%)
GE   104.29 (-1.61%)
AMD   118.46 (+1.78%)
MU   68.02 (-0.37%)
T   25.86 (-0.19%)
F   16.33 (+1.81%)
ACB   7.63 (-0.39%)
DIS   170.76 (+0.12%)
PFE   42.56 (-0.56%)
BA   215.37 (-0.37%)
AMC   41.24 (+0.88%)
ASX:CP1

CannPal Animal Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive CP1 News and Ratings via Email

Sign-up to receive the latest news and ratings for CannPal Animal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$802,623.00
Book Value
A$0.01 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












CannPal Animal Therapeutics (ASX:CP1) Frequently Asked Questions

What stocks does MarketBeat like better than CannPal Animal Therapeutics?

Wall Street analysts have given CannPal Animal Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CannPal Animal Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are CannPal Animal Therapeutics' key executives?

CannPal Animal Therapeutics' management team includes the following people:
  • Mr. Layton Patrick Mills, Founder, MD & Director
  • Dr. Margaret Curtis, Head of Clinical Devel. and R&D
  • Mr. Baden Maxwell Bowen, CFO & Company Sec.
  • Dr. Rayson Tan, Chief Scientific Officer & Member of Advisory Board

What is CannPal Animal Therapeutics' stock symbol?

CannPal Animal Therapeutics trades on the ASX under the ticker symbol "CP1."

How much money does CannPal Animal Therapeutics make?

CannPal Animal Therapeutics has a market capitalization of $0.00 and generates $802,623.00 in revenue each year.

What is CannPal Animal Therapeutics' official website?

The official website for CannPal Animal Therapeutics is www.cannpal.com.

How can I contact CannPal Animal Therapeutics?

The company can be reached via phone at 61 2 6108 3622.


This page was last updated on 10/21/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.